Anti-VEGF Therapy - Managing Challenging Case Scenarios

The management of ocular neovascular diseases received a major shot in the arm with the advent of anti-VEGF (vascular endothelial growth factor) therapy at the turn of the millennium. The anti-VEGF triumvirate – bevacizumab (Avastin), ranibizumab (Lucentis) and Pegaptanib sodium (Macugen), especially the former two, constitute the bulk of therapy for exudative and neovascular retinal pathologies.1-6 The use of these agents have brought along with them challenges and conundrums of their own. We have a few such challenging clinical scenarios with eminent experts providing their take and therapeutic strategies.